89bio, Inc. ETNB · Stock Open 89bio, Inc. in new tab
89bio, Inc. Analysis (ETNB)
Is 89bio, Inc. a good investment? 89bio, Inc. (ETNB) is currently trading at 14.84 USD. Market analysts have a consensus price target of 30.38 USD. This suggests a potential upside from current levels.
Earnings Schedule: 89bio, Inc. is expected to release its next earnings report on Nov. 6, 2025. The market consensus estimate for Forward EPS is -2.87.
Investor FAQ
Does 89bio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is 89bio, Inc.?
89bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 6, 2025. The company currently has a trailing EPS of -3.69.
Company Profile
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
Community Discussion